Trust Co. of Virginia VA Cuts Stake in Pfizer Inc. (NYSE:PFE)

Trust Co. of Virginia VA reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,788 shares of the biopharmaceutical company’s stock after selling 3,862 shares during the period. Trust Co. of Virginia VA’s holdings in Pfizer were worth $938,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Advisor OS LLC raised its holdings in Pfizer by 1.0% in the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after buying an additional 365 shares during the period. Safeguard Investment Advisory Group LLC raised its holdings in Pfizer by 3.9% in the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after buying an additional 371 shares during the period. Lantz Financial LLC raised its holdings in Pfizer by 1.3% in the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after buying an additional 381 shares during the period. King Wealth Management Group grew its position in Pfizer by 2.4% in the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 388 shares in the last quarter. Finally, Advance Capital Management Inc. grew its position in Pfizer by 4.0% in the fourth quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock valued at $293,000 after acquiring an additional 391 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Pfizer stock traded up $0.18 during mid-day trading on Friday, reaching $27.98. The company’s stock had a trading volume of 33,189,215 shares, compared to its average volume of 34,031,364. The firm has a market cap of $158.55 billion, a price-to-earnings ratio of -466.42, a PEG ratio of 1.09 and a beta of 0.70. The business has a 50 day moving average price of $27.90 and a 200-day moving average price of $27.69. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.23 earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.00%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analyst Weigh In

Several analysts have issued reports on PFE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Morgan Stanley increased their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.